ClinicalTrials.gg
RecruitingNCT06263660Updated Apr 20, 2026

Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression

A Phase 2 interventional study of Keto-like supplement and Placebo in Depression, sponsored by Laureate Institute for Brain Research, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Laureate Institute for Brain Research, Inc. · Phase 2, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Depression by Laureate Institute for Brain Research, Inc. — 2 open to participants now, 4 under way, none of them phase 3. Depression · Laureate Institute for Brain Research, Inc..

Planned enrollment
5th of 10
75 · median 66
Started
2024
the only one that year
Phase 2
2 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Depression by Laureate Institute for Brain Research, Inc., this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2024, is one of 2 in phase 2, and was the 12th registered.

Depression

8,602 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

2 of the 12 studies in Depression by Laureate Institute for Brain Research, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Depression by Laureate Institute for Brain Research, Inc., or all of them as a file.
02

Study summary

This study aims to determine whether a keto-like supplement relative to placebo results in functional brain changes during fMRI tasks evaluating positive and negative valence in individuals with moderate to severe depression. In this double-blind randomized placebo-controlled trial, 75 individuals with a Patient Health Questionnaire (PHQ-9) scale score ≥ 10 (MDD) will be enrolled to participate in an 8-week treatment study to obtain 60 completers. Participants will be randomized with a 1-1 ratio to receive the keto-like supplement (n= 30 completers) or placebo (n=30 completers) taken orally three times per day for 8 weeks. Participants will undergo a 10.5-hour screening/baseline evaluation visit split over 2 days at week 0 including questionnaires, neuroimaging before and after supplement or placebo administration and blood draws, office visits at week 2 (1.5 hours), week 4 (3 hours), week 6 (0.5 hours), week 8 (6 hours), a follow-up visit at week 10 (1.5 hours) and two phone calls between visits (weeks 1 and 3) during which a brief clinical assessment will be obtained (10 minutes each). The total time involved in the study is approximately 23.5 hours.

03

Conditions studied

  • Depression

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets the Diagnostic and statistical manual - 5 () diagnostic criteria for MDD without psychotic features (past or present), as confirmed by the M.I.N.I v7.0
  • PHQ-9 score of ≥10
  • C-Reactive Protein (CRP) value > 1
  • Age 18-65
  • Consent ability and written consent
  • (BMI) between 19 and 38 kg/m2
  • Medically stable based on clinical laboratory tests, medical history and vital signs
  • No intention to become pregnant during the study
  • A woman of must have a negative serum pregnancy test at screening
  • Consent that possible random finding is reported (e.g. brain abnormality during imaging)

Exclusion criteria

Exclusion Criteria:

  • Has a current or recent history of suicidality
  • Has a history of moderate or severe substance or alcohol use disorder according to criteria, except nicotine or caffeine, within 12 months before screening
  • Has positive test result(s) for alcohol or drugs of abuse (including methadone, opiates, cocaine, cannabinoids, amphetamine/methamphetamine and ecstasy)
  • Has a current diagnosis of a psychotic disorder (e.g. schizophrenia, bipolar disorder), an eating disorder (e.g. anorexia, bulimia), or learning disability or a personality disorder that is considered by the investigator to interfere with the ability of the subject to adhere to the protocol (e.g. narcissistic personality, borderline personality disorder)
  • Change in medication dose and/or frequency within the last 6 weeks. Participants must be on stable medications for 6 weeks prior to enrollment.
  • Plans to change medication dose/frequency during the course of the study. Must plan to remain on stable dose for the duration of the study, unless otherwise indicated by their provider during the course of the study.
  • Plans to take vitamins and/or mineral supplements during the study. Must refrain for the duration of the study
  • Unable to complete MRI scans
  • Is a woman who is pregnant or breast feeding
  • Plans to conceive a child while enrolled in this study or within 3 months after the last dose of the keto-like supplement
  • Has received an drug/vaccines, used an invasive investigational medical device within 60 days before the planned first dose of the keto-like supplement or has participated in 2 or more interventional clinical studies in the previous 1 year, or is currently enrolled in any drug or non-drug interventional study.
  • Has had major surgery, (i.e. requiring general anesthesia) within 12 weeks before screening, or will not have fully recovered from surgery, or has surgery planned during the time they are expected to participate in the study.
  • Intake of Omega 3 fatty acids (DHA, EPA, fish oil supplements)
  • Significant cognitive impairment, clinically relevant or progressive disease (e.g., liver, kidney, cardiovascular system, respiratory tract, vascular system, brain, metabolism, thyroid) that could affect the course of the study
  • Known metabolic disorders (e.g., fatty acid oxidation disorders, ketolysis/ketogenesis or glucogenesis disorder, hyperinsulinism (e.g., pancreatic neuroendocrine tumor), pyruvate carboxylase deficiency, Type 1 and Type 2 diabetes
  • Allergy to Stevia sweetener, malic acid or orange flavoring
  • Concern for inability to maintain adherence to the keto-like supplement administration protocol
  • Currently practicing a ketogenic or paleo diet or planning to do so during the study period.
  • Change in body weight of more than 5 kg within one month before the start of the intervention
  • Medical, psychiatric or other conditions that restrict the patient's following abilities: to interpret the study information, to give , to adhere to the rules of the protocol, or to complete the study
  • to MRI examinations [persons with metallic implants (e.g., intracranial metal clips) and carriers of electronic devices (e.g., pacemaker) or persons with claustrophobia]
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Active comparator
    Keto-like supplement

    Participants will receive standardized 9.25g stick packs of the keto-like supplement. The study participants will take one of these stick packs dissolved in water three times a day (morning, noon, and evening) for 8 weeks.

    Dietary Supplement: Keto-like supplement

  • Placebo comparator
    Placebo

    Participants will receive standardized 9.25g stick packs of placebo. The study participants will take one of these stick packs dissolved in water three times a day (morning, noon, and evening) for 8 weeks.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementKeto-like supplement

    Participants will consume 9.25g stick packs of the keto-like supplement dissolved in water 3 times per day for 8 weeks.

  • Dietary supplementPlacebo

    Participants will consume 9.25g stick packs of placebo dissolved in water 3 times per day for 8 weeks.

06

What researchers measure

Primary outcomes

  1. BOLD response during Monetary Incentive Delay Task

    P5vP0 contrast in the nucleus accumbens during the Monetary Incentive Delay Task

    Time frame: week 0 pre, week 0 post, week 8

Secondary outcomes

  1. BOLD response during Adjective Task

    SELFvWORD contrast in the medial prefrontal cortex during the Adjective task

    Time frame: week 0 pre, week 0 post, week 8

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

Of 144 non-industry phase 2 interventional studies under Depression, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 35 months is close to that.

Counting every sponsor, half of 198 studies reached it within 31 months; a quarter within 18 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2024
First posted
Feb 16, 2024
StartActual
Jan 9, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 2027
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06263660
Lead sponsor
Laureate Institute for Brain Research, Inc.
Responsible party
Sponsor
First posted
Feb 16, 2024
Start date
Jan 9, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 20, 2026

Study contacts

Teresa Victor, PhD
Contact
tvictor@laureateinstitute.org
918-502-5108
Colleen McCallum
Contact
cmccallum@laureateinstitute.org
918-502-5180
Martin Paulus, MD
principal investigator · Laureate Institute for Brain Research

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion